Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and ...

A panelist discusses how detailed clinical assessments of hematologic parameters, symptom burden, thrombotic risk, and molecular markers inform necessary treatment modifications when initial ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

We recently published a list of 10 Best Healthcare Stocks For Long-Term Investment. In this article, we are going to take a ...

Ono Pharmaceutical Co. Ltd. struck a licensing deal with Ionis Pharmaceuticals Inc. for sapablursen, which is in phase II trials for polycythemia vera. Under terms, Osaka, Japan-based Ono gains an ...

Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy by Ionis to treat polycythemia ...

Ionis’ drug, called sapablursen, is currently being tested in a Phase 2 trial in people with polycythemia vera.

Japanese drugmaker Ono (TYO: 4528) has entered into a license agreement with USA-based Ionis Pharmaceuticals (Nasdaq: IONS) ...

Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...

Japan's Ono Pharmaceutical is handing over $280 million upfront to acquire Ionis Pharmaceuticals’ phase 2-stage antisense ...